According to a French national cohort study of an estimated 1,89,289 patients affected by IBD, those receiving combination therapy of thiopurine and anti-TNF agents had a 6-fold greater risk of lymphoma compared to those receiving monotherapy of either drug (13). The gene discussed is TNF; the disease is lymphoma.